MELanoma Brain Metastasis Treated With CYberknife

Summary

Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life. In recent years, treatments have improved significantly thanks to advances in surgery, radiotherapy, immunotherapy, and targeted therapy. These new treatments have greatly increased survival rates for patients with metastatic melanoma. This study focuses on stereotactic radiosurgery, a highly precise form of radiotherapy used to treat brain metastases. Researchers want to better understand how this treatment works when combined with immunotherapy or targeted therapy, and whether the timing and sequence of treatments can improve outcomes. Between 2026 and 2028, patients treated at the IEO for melanoma brain metastases will be observed and their clinical data collected. The goal is to improve future treatment strategies and help doctors choose the best therapeutic approach for each patient.

Eligibility

Inclusion Criteria:

* Age \> 18
* Written informed consent for treatment and research purposes
* Melanoma Brain Metastases (MBM) diagnosed with brain MRI/CT
* MBM treatable with stereotactic radiotherapy
* Systemic therapy (immunotherapy, target therapy, or both) is allowed, as concurrent or non-concurrent treatment with stereotactic radiotherapy

Exclusion Criteria:

* Leptomeningeal neoplastic infiltration
* Previous whole-brain radiotherapy or surgical removal of brain metastases
* Patients with histological diagnosis of non-cutaneous melanoma (e.g. uveal melanoma)

Conditions2

Browse More Trials